Skip Navigation

European Heart Journal 2003 24(20):1824-1832; doi:10.1016/j.ehj.2003.07.003
Copyright © 2003 by the European Society of Cardiology.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (11)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Liu, P.-Y.
Right arrow Articles by Chen, J.-H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liu, P.-Y.
Right arrow Articles by Chen, J.-H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Clinical research

Prognostic value and the changes of plasma levels of secretory type II phospholipase A2 in patients with coronary artery disease undergoing percutaneous coronary intervention

Ping-Yen Liua,b, Yi-Heng Lia, Wei-Chuan Tsaia, Ting-Hsing Chaoa, Liang-Miin Tsaia, Hua-Lin Wuc and Jyh-Hong Chena,*

a Division of Cardiology, Department of Internal Medicine, College of Medicine, National Cheng-Kung University Medical Center, Tainan, Taiwan
b Institute of Clinical Medicine, College of Medicine, National Cheng-Kung University Medical Center, Tainan, Taiwan
c Department of Biochemistry, College of Medicine, National Cheng-Kung University Medical Center, Tainan, Taiwan

* Correspondence to: Jyh-Hong Chen, MD, PhD, FACC, Division of Cardiology, Department of Internal Medicine, National Cheng-Kung University Medical Center, 138 Sheng-Li Road, Tainan 704, Taiwan. Tel: +886-6-235-3535 ext. 2389; fax: +886-6-275-3834
E-mail address: jyhhong{at}mail.ncku.edu.tw

Received 22 May 2003; revised 4 July 2003; accepted 17 July 2003

Abstract

Aim To evaluate the serial changes of plasma secretory type II phospholipase A2(sPLA2), C-reactive protein (CRP) and cardiac injury markers in coronary artery disease (CAD) patients undergoing percutaneous coronary intervention (PCI) and their prognostic impacts.

Methods and results Plasma levels of sPLA2, CRP, creatine kinase (CK), CK-MB and troponin-T were measured in 247 consecutive CAD patients receiving PCI procedure and 100 control subjects without CAD. In CAD group, serial blood samples were taken before coronary angiography, after coronary angiography, immediately after PCI, 24-h and 48-h after PCI. The sPLA2and CRP levels did not change after coronary angiography. The level of sPLA2significantly increased immediately after PCI. Creatine kinase and cardiac injury markers did not rise immediately after PCI, but elevated significantly at 24h after intervention. After a 2-year follow up, increased sPLA2(>450ng/dl) after PCI, smoking and diabetes mellitus were the independent risk factors for subsequent coronary events (odds ratios 2.1, 2.3 and 3.1, respectively) in patients with CAD.

Conclusion The present study showed that PCI might cause immediate elevation of circulating levels of sPLA2following the mechanical disruption of coronary plaque, and the elevated level of sPLA2had significant prognostic impact.

Key Words: Acute coronary syndrome • Inflammation • Percutaneous coronaryIntervention • Prognosis


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Type II secretory phospholipase A2: The emerging role of biochemical markers of plaque inflammation
Jan J. Piek and Robbert J. de Winter
EHJ 2003 24: 1804-1806. [Extract] [Full Text]  



This article has been cited by other articles:


Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
Z. Mallat, J. Benessiano, T. Simon, S. Ederhy, C. Sebella-Arguelles, A. Cohen, V. Huart, N. J. Wareham, R. Luben, K.-T. Khaw, et al.
Circulating Secretory Phospholipase A2 Activity and Risk of Incident Coronary Events in Healthy Men and Women: The EPIC-NORFOLK Study
Arterioscler. Thromb. Vasc. Biol., May 1, 2007; 27(5): 1177 - 1183.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
P. T.E. Wootton, F. Drenos, J. A. Cooper, S. R. Thompson, J. W. Stephens, E. Hurt-Camejo, O. Wiklund, S. E. Humphries, and P. J. Talmud
Tagging-SNP haplotype analysis of the secretory PLA2IIa gene PLA2G2A shows strong association with serum levels of sPLA2IIa: results from the UDACS study
Hum. Mol. Genet., January 15, 2006; 15(2): 355 - 361.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
N. Saleh, B. Svane, L.-O. Hansson, J. Jensen, T. Nilsson, O. Danielsson, and P. Tornvall
Response of Serum C-Reactive Protein to Percutaneous Coronary Intervention Has Prognostic Value
Clin. Chem., November 1, 2005; 51(11): 2124 - 2130.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
Z. Mallat, Ph. G. Steg, J. Benessiano, M.-L. Tanguy, K. A. Fox, J.-P. Collet, O. H. Dabbous, P. Henry, K. F. Carruthers, A. Dauphin, et al.
Circulating Secretory Phospholipase A2 Activity Predicts Recurrent Events in Patients With Severe Acute Coronary Syndromes
J. Am. Coll. Cardiol., October 4, 2005; 46(7): 1249 - 1257.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
S. M. Boekholdt, T. T. Keller, N. J. Wareham, R. Luben, S. A. Bingham, N. E. Day, M. S. Sandhu, J. W. Jukema, J. J.P. Kastelein, C. E. Hack, et al.
Serum Levels of Type II Secretory Phospholipase A2 and the Risk of Future Coronary Artery Disease in Apparently Healthy Men and Women: The EPIC-Norfolk Prospective Population Study
Arterioscler. Thromb. Vasc. Biol., April 1, 2005; 25(4): 839 - 846.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.